Choosing the right anti-TNF therapy
According to Dr. Schwartz, the primary factors that must be considering when deciding on which anti-TNF therapy is the right one to treat Crohn's disease should always be safety and efficacy. The safety and efficacy of the four primary medications currently used to treat Crohn's disease (adalimumab, natalizumab, certolizumab, and infliximab) seem to all rate among similar marks on the scale. Schwartz states that because the three drugs are similar in safety and efficacy, perhaps the deciding factor may lie in the mode of delivery, patient adherence, and patient preference.
Anti-TNF Treatment in Crohn's Disease and Risk of Bowel Resection: A Population Based Cohort Study. (2017, July 29). [Web]. In IBD Watch. Retrieved from: http://www.ibdwatch.org/most-recent/anti-tnf-treatment-in-crohns-disease-and-risk-of-bowel-resection-a-population-based-cohort-study/
Infliximab: The First Anti-TNF Drug Approved for Crohn’s (n.d.). [Web]. In Crohn's Disease Focus. Retrieved on 09/09/2017 from: http://crohnsdiseasefocus.com/crohns-disease-treatment/treatment-of-crohns-disease-with-anti-tnf-drugs/
Schwartz, D. (n.d.). Refining the Therapeutic Landscape in Anti-TNF Therapy for Crohn's Disease: An Expert Interview With David A. Schwartz, MD. [Web]. In Medscape. Retrieved on 09/09/2017 from: http://www.medscape.org/viewarticle/574122